Press "Enter" to skip to content

Eli Lilly is the best of both worlds — a recession-resistant stock with major growth potential

Traders work beneath monitors displaying Eli Lilly signage on the floor of the New York Stock Exchange.

Michael Nagle | Bloomberg | Getty Images

The year ahead is pivotal for Eli Lilly (LLY) as the pharmaceutical giant looks to advance drugs in its stellar pipeline. Executives detailed reasons for optimism at a major industry gathering this week.